PHXM PHAXIAM THERAPEUTICS

Informazioni mensili relative al numero totale dei diritti di voto e delle azioni che compongono il capitale sociale – 31 luglio 2020

Informazioni mensili relative al numero totale dei diritti di voto e delle azioni che compongono il capitale sociale – 31 luglio 2020

LIONE, Francia, Aug. 07, 2020 (GLOBE NEWSWIRE) --

Articolo 223-16 del regolamento generale dell’Autorité des Marchés Financiers francese

Lione – Francia

Mercati azionari:

Euronext Paris da Euronext (Segmento di mercato C - Codice ISIN: FR0011471135 - Simbolo: ERYP) e

Nasdaq Global Select Market degli Stati Uniti (Simbolo: ERYP)

Sito Web:

DataTotale delle azioni che compongono il capitale socialeTotale dei diritti di voto lordi (1)Totale dei diritti di voto netti (2)
31 dicembre 201917 940 03519 534 01419 531 514
31 gennaio 202017 940 03519 534 26019 531 760
29 febbraio 202017 940 03519 534 26019 531 760
31 marzo 202017 940 03519 536 73619 534 236
30 aprile 202017 940 03519 536 80619 534 306
30 maggio 202017 940 03519 489 41019 486 910
30 giugno 202017 956 11519 511 88519 509 385
31 luglio 202018 081 84319 758 34219 755 842



(1)Il numero dei diritti di voto lordi (o diritti di voto "teorici") è utilizzato come base per il calcolo del superamento della soglia. Ai sensi dell’articolo 223-11 del regolamento generale dell'Autorité des Marchés Financiers, questo numero è calcolato sulla base di tutte le azioni con diritto di voto unico e doppio, ivi comprese le azioni senza diritto di voto.
(2)Escluse le azioni proprie.
  

EN
07/08/2020

Underlying

PHXMPHAXIAM THERAPEUTICS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PHAXIAM THERAPEUTICS

 PRESS RELEASE
Free
PHXM PHAXIAM THERAPE...

PHAXIAM Therapeutics announces high coverage performance of its two an...

PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains PHAXIAM Therapeutics announces high coverage performanceof its two anti-Staphylococcus aureus phages over clinical strains Data from PHAXIAM’s phagogram, first CE-marked Phage Susceptibility Test (PST), showed 98% response rate over 105 clinical S. aureus strains Lyon (France) et Cambridge (MA, US), October 9, 2023 at 10:05pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced a very high spectrum of activity of its anti-S. aureus (PP1493 and PP181...

October 9, 2023 1 EN
 PRESS RELEASE
Free
PHXM PHAXIAM THERAPE...

PHAXIAM Therapeutics annonce un niveau de performance élevé de ses deu...

PHAXIAM Therapeutics annonce un niveau de performance élevé de ses deux phages anti-Staphylococcus aureus sur des souches cliniques PHAXIAM Therapeutics annonce un niveau de performance élevé de ses deux phages anti-Staphylococcus aureus sur des souches cliniques Les données obtenues à partir du phagogramme développé par PHAXIAM, le premier test de sensibilité aux phages disposant du marquage CE, ont montré un taux de réponse de 98% sur 105 souches cliniques de S. aureus Lyon (France) et Cambridge (MA, US), le 9 octobre 2023 - 22h05 CEST – PHAXIAM Therapeutics (Nasdaq & Euronext : PHXM), ...

October 9, 2023 1 EN
 PRESS RELEASE
Free
PHXM PHAXIAM THERAPE...

PHAXIAM Receives Compliance Notice from Nasdaq

PHAXIAM Receives Compliance Notice from Nasdaq PHAXIAM Receives Compliance Notice from Nasdaq Lyon (France) et Cambridge (MA, US), October 4, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced that it has received confirmation from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2). With closing bid price of PHAXIAM’s American Depositary Shares (“ADSs”) above $1.00 per ADS for the 10 consecutive business days from September 18 through September 29, 2023, PHAXIAM has regained compliance with Listing Rule 5550(a)(2). On October 7, 202...

October 4, 2023 1 EN
 PRESS RELEASE
Free
PHXM PHAXIAM THERAPE...

PHAXIAM reçoit un avis de conformité du Nasdaq

PHAXIAM reçoit un avis de conformité du Nasdaq PHAXIAM reçoit un avis de conformité du Nasdaq Lyon (France) et Cambridge (MA, US), le 4 octobre 2023, 22h05 CEST – PHAXIAM Therapeutics (Nasdaq & Euronext : PHXM), annonce aujourd'hui avoir reçu la confirmation du Nasdaq d’être à nouveau en conformité avec la règle de cotation 5550(a)(2). Avec un cours de clôture des American Depositary Shares (« ADS ») de PHAXIAM supérieur à 1,00 $ par ADS pendant les 10 jours ouvrables consécutifs du 18 septembre au 29 septembre 2023, PHAXIAM est de nouveau en conformité avec la règle de cotation 5550(a)(2...

October 4, 2023 1 EN
 PRESS RELEASE
Free
PHXM PHAXIAM THERAPE...

PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collab...

PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration Strategic research partnership between PHAXIAM Therapeutics and Vetophage, a biotechnology company specialized in veterinary phage therapy Combining expertise in the research of new phages and phage endolysins that could be applied to human healthExclusive phage and endolysin licensing options in human health for PHAXIAM Therapeutics Lyon (France) and Cambridge (MA, US), October 03, 2023 – 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq &...

October 3, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch